Veratridine

Veratridine is a steroidal alkaloid derived from Veratrum species plants that acts as a potent activator of voltage-gated sodium channels (Nav), preventing their inactivation and causing persistent depolarization of excitable cells. It is classified strictly as a research-grade neurotoxin with no approved therapeutic or dietary supplement applications in humans.

Origin & History

Veratridine is a steroidal alkaloid (C₃₆H₅₁NO₁₁) extracted from plants in the Liliaceae family, particularly Schoenocaulon officinale (sabadilla) seeds and Veratrum album rhizomes. It exists in plants as a glycosidal complex and is purified to ≥98% purity for research purposes through HPLC extraction methods.

Historical & Cultural Context

Unlike many plant alkaloids, veratridine has minimal documented use in traditional medicine systems due to its recognized toxicity. Veratrum and Schoenocaulon plants were historically used as insecticides and pesticides in agricultural settings. 19th-century pharmaceutical experiments with veratridine for hypertension were abandoned due to its narrow therapeutic window and severe toxicity.

Health Benefits

• No therapeutic benefits established - veratridine is a neurotoxin with no approved clinical uses (no human trials)
• Research tool only - used to study sodium channel dynamics in laboratory settings (in vitro evidence only)
• Preclinical cancer research - showed potential chemosensitivity enhancement through mortalin-2 inhibition (cell studies only, Abdullah et al. 2015)
• Potential Nav1.7 channel inhibition suggesting theoretical analgesic properties (mechanistic studies only, not pursued clinically)
• Historical pesticide use - toxicity exploited for agricultural pest control, not human health

How It Works

Veratridine binds to site 2 of voltage-gated sodium channels (Nav1.x isoforms), specifically interacting with transmembrane segments IS6 and IVS6, locking channels in a persistently open conformation and blocking fast inactivation. This sustained sodium influx causes continuous membrane depolarization, triggering excessive neurotransmitter release, particularly catecholamines such as norepinephrine and dopamine, from nerve terminals. At the cellular level, the resultant Na+ overload drives secondary Ca2+ entry via reverse-mode Na+/Ca2+ exchange, ultimately leading to cytotoxicity and cell death.

Scientific Research

No human clinical trials or RCTs exist for veratridine - it is not approved for clinical use. The only published biomedical research is a preclinical oncology study (Abdullah et al., Oncotarget 2015;6(27):23561-81) demonstrating UBXN2A-dependent mortalin-2 inhibition in cell models. All other evidence consists of in vitro pharmacological characterization studies using veratridine as a research tool.

Clinical Summary

There are zero published randomized controlled trials or approved human clinical studies investigating veratridine as a therapeutic agent. All available evidence originates from in vitro cell-based assays and rodent models; for example, preclinical studies in murine cancer cell lines demonstrated that veratridine enhanced chemosensitivity to agents like doxorubicin, but no human translation has been pursued. A small number of animal electrophysiology studies used veratridine at nanomolar concentrations (typically 10–100 nM) to characterize Nav isoform pharmacology, confirming its utility as a mechanistic probe rather than a drug candidate. The overall evidence base is exclusively preclinical, and no dosing regimen, bioavailability data, or efficacy endpoint has been established for humans.

Nutritional Profile

Veratridine is a steroidal alkaloid (C36H51NO11, molecular weight 673.79 g/mol) isolated from Veratrum album (white hellebore) and Schoenocaulon officinale (sabadilla seeds) — it is a pure pharmacologically active compound with no nutritional value. Macronutrient classification: not applicable as a food ingredient. Contains no dietary protein, carbohydrates, fiber, vitamins, or minerals in any meaningful nutritional sense. As a steroidal alkaloid, it possesses a lipid-soluble polycyclic carbon skeleton structurally related to cholesterol-derived compounds, but contributes no caloric value in any established dietary context. Bioactive compound concentration in source plants: veratridine constitutes approximately 0.2–1.5% of total alkaloid content in Veratrum species, with total plant alkaloid content ranging 0.5–2.0% dry weight. The compound is highly bioavailable due to lipophilicity (estimated logP ~2.5–3.5), readily crossing biological membranes including the blood-brain barrier. Oral absorption is documented but precise human bioavailability data is absent due to toxicity precluding human pharmacokinetic studies. In laboratory preparations, veratridine is typically handled as a pure isolated compound (>98% purity) dissolved in DMSO or ethanol at concentrations of 1–10 mM stock solutions. No Dietary Reference Intake (DRI), Tolerable Upper Limit, or nutritional recommendation exists — the compound is classified as a neurotoxin with a lethal dose (LD50) of approximately 1.35 mg/kg (intravenous, mouse model).

Preparation & Dosage

No clinically established dosage exists - veratridine is a neurotoxin contraindicated for human consumption. Research concentrations use micromolar ranges in cell culture and mg/kg doses in animal studies, but these are not therapeutic recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - toxic compound with no therapeutic uses

Safety & Interactions

Veratridine is acutely toxic to humans even at low doses; ingestion of Veratrum-containing plants has caused severe bradycardia, hypotension, prolonged QT interval, ventricular arrhythmias, and respiratory depression requiring emergency intervention. It has no established safe human dose, and accidental poisoning cases report symptom onset within 30 minutes of exposure involving nausea, vomiting, paraesthesia, and cardiovascular collapse. Veratridine would be expected to dangerously potentiate the effects of other sodium channel-active drugs including local anesthetics (lidocaine, bupivacaine), antiepileptics (carbamazepine, phenytoin), and antiarrhythmics. It is absolutely contraindicated in pregnancy, nursing, pediatric populations, and any individual with cardiovascular, neurological, or renal conditions, and it should never be self-administered or purchased as a supplement.